Euphrasia eye drops in preterm neonates with ocular discharge: a randomized double-blind placebo-controlled trial

Meier-Girard, Delphine; Gerstenberg, Gisa; Stoffel, Liliane; Kohler, Therese; Klein, Sabine D.; Eschenmoser, Marco; Mitter, Vera Ruth; Nelle, Mathias; Wolf, Ursula (2020). Euphrasia eye drops in preterm neonates with ocular discharge: a randomized double-blind placebo-controlled trial. Frontiers in Pediatrics, 8(449), p. 449. Frontiers 10.3389/fped.2020.00449

[img]
Preview
Text
2020_EuphrasiaEyeDropsPretermNeonatesOcularDischarge_FrontiersInPediatrics.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (539kB) | Preview

Aim: To investigate whether the early administration of Euphrasia eye drops® in preterm neonates presenting with ocular discharge fosters the resolution of the ocular discharge and reduces the need for topical antibiotic therapy, as compared to placebo.
Methods: We conducted a randomized double-blind placebo-controlled trial at the University Children’s Hospital Bern, Switzerland. Preterm neonates with white, yellow, or green ocular discharge were included. Infants were randomly assigned (1:1) to the Euphrasia arm (Euphrasia eye drops®, Weleda AG, Arlesheim) or the placebo arm (NaCl 0.9%). Euphrasia or placebo was administrated at a dose of one drop in each eye four times a day over a period of 96 hours. The primary outcome was the treatment success, defined as no ocular discharge at 96 hours and no use of topical antibiotic therapy during the 96-hour intervention.
Results: A total of 114 neonates were screened and 84 were randomized. Among neonates in the Euphrasia arm, 22 (55.0%) achieved our primary outcome compared to 21 (51.2%) in the placebo arm (p=0.85). In the Euphrasia arm, time to resolution of reddening tended to fall within the shorter bracket of 24 to 48 hours (24 (92.3%) versus 12 (80.0%) in the placebo arm, p=0.34) and relapse or first signs of reddening during the 96-hour intervention tended to be lower (3 (7.9%) eyes versus 8 (18.2%) eyes in the placebo arm, p=0.17). Tearing at 96 hours tended to be lower in the Euphrasia arm (5 (12.8%) eyes in the Euphrasia arm versus 12 (27.3%) eyes in the placebo arm, p=0.10).
Discussion: Euphrasia did not significantly improve treatment success, defined as no ocular discharge at 96 hours and no use of topical antibiotic therapy during the 96-hour intervention. However, results suggest that Euphrasia may be of benefit for symptoms such as reddening and tearing, and thus improve the comfort of patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Medical Education > Institute of Complementary and Integrative Medicine (IKIM)
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology

UniBE Contributor:

Meier-Girard, Delphine; Gerstenberg, Gisa Almut; Klein, Sabine; Mitter, Vera Ruth and Wolf, Ursula

Subjects:

600 Technology > 610 Medicine & health
600 Technology > 610 Medicine & health > 615 Pharmacology & therapeutics, prescription drugs

ISSN:

2296-2360

Publisher:

Frontiers

Funders:

[UNSPECIFIED] Institute of Complementary and Integrative Medicine, University of Bern
[UNSPECIFIED] Department of Neonatology, Children’s University Hospital, Bern, University of Bern

Language:

English

Submitter:

Delphine Meier-Girard

Date Deposited:

22 Sep 2020 08:00

Last Modified:

27 Sep 2020 02:51

Publisher DOI:

10.3389/fped.2020.00449

PubMed ID:

32850558

Uncontrolled Keywords:

ocular discharge, congenital nasolacrimal duct obstruction, preterm neonate, Euphrasia drops, complementary medicine.

BORIS DOI:

10.7892/boris.146575

URI:

https://boris.unibe.ch/id/eprint/146575

Actions (login required)

Edit item Edit item
Provide Feedback